THROMBOPHILIA AND INTENSITY OF THE INTRAVASCULAR MICROCOAGULATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ATHEROTHROMBOSIS

Aim. To study the intensity of the intravascular microcoagulation in patients with atherothrombosis (AT), chronic obstructive pulmonary disease (COPD) and thrombophilia.

Material and methods. 115 patients were enrolled into the study: 37 patients with COPD (22 with thrombophilia and 15 without thrombophilia); 37 patients with AT (23 with thrombophilia and 14 without thrombophilia); 41 patients with COPD+AT (24 with thrombophilia and 17 without thrombophilia). In the control group 53 healthy people (39 with thrombophilia and 14 without thrombophilia) were included. Median age was 62 (56.5, 69) years. The intensity of intravascular microcoagulation was measured: platelet factor 4 (PF4) by ELISA, D-dimer by ELISA, XIIa-dependent fibrinolysis (time). Polymerase chain reaction was used for detection of such trombophilia parameters as Leiden mutation, prothrombin gene mutation 20210A, mutation in the gene of methylenetetrahydrofolate reductase (MTHFR) and plasminogen activator inhibitor-1 (PAI-1).

Results. The level of PF4 and D-dimer was significantly higher while fibrinolytic activity was lower in COPD (103.5 ME/ml, 70 ng/ml, 650 s, respectively), AT (127.1 ME/ml, 96,9 ng/ml, 850 s, respectively) and COPD+AT (136.5 ME/ml, 106.5 ng/ml, 1148 s, respectively) groups as compared with the control group (p<0.05). When analyzing the level of intravascular coagulation parameters in patients with thrombophilia and without it, levels of PF4, D-dimer and XIIa-dependent fibrinolysis (time) were significantly higher in thrombophilia subgroups among all patients (p<0.05). In patients with thrombophilia levels of these parameters were significantly higher in those with two or more thrombophilia gene polymorphisms than with one (p<0.01).

Conclusion. The intensity of intravascular microcoagulation increases in patients with thrombophilia, atherothrombosis and COPD.

1. Bokarev I.N., Popova L.V. Venous thromboembolism and pulmonary embolism. Moscow: MIA, 2013. Russian (Бокарев И.Н., Попова Л.В. Венозный тромбоэмболизм и тромбоэмболия легочной артерии. М.: МИА; 2013).

2. Kozlovskaya N.L, Bobrova L.A. Genetic thrombophilia and kidneys. Klinicheskaya nefrologiya 2009; (3): 23-34. Russian (Козловская Н.Л, Боброва Л.А. Генетическая тромбофилия и почки. Клиническая нефрология 2009; (3): 23-34).

3. Vorob'ev A.I. Hypercoagulable syndrome in internal medicine. Report on the MGNOT meeting; November 12 2008. Moskovskiy doktor. Vestnik Moskovskogo gorodskogo nauchnogo obshchestva terapevtov 2009; 3(92): 1, 4-5. Russian (Воробьев А.И. Гиперкоагуляционный синдром в клинике внутренних болезней. Доклад на заседании МГНОТ 12 ноября 2008 г. Московский доктор. Вестник Московского Городского Научного Общества Терапевтов 2009; 3(92): 1, 4-5).

4. Heit J. A. Thrombophilia : common questions on laboratory assessment and management Hematology. Am Soc Hematol Educ Program 2007; 1: 127-35.

5. The Global initiative for chronic Obstructive Lung Disease 2014. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf. Accessed by 12.06.2014.

6. Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 89-96.

7. Bokarev I.N. Internal medicine. Moscow: MIA; 2009: 21-42. Russian (Бокарев И.Н. Внутренние болезни. М.: МИА; 2009: 21-42).

8. Levine SP, Lindenfeld J, Ellis JB, et al. Increased Plasma Concentrations of Platelet Factor 4 in Coronary Artery Disease. Circulation 1981;64:626-32/

9. Buyukasyk NS, Ileri M, Alper A, et al. Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin Cardiol 2004; 27:154-8.

10. Laghrissi-Thode F, Wagner WR, Pollock PC, Finkel MS. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42: 290-5.

11. Alehagen U, Dahlström U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004;92(6):1250-8.

12. Singh AK, Gupta V, Singh N, et al. Role of Immunoturbidimetric plasma fibrin D-dimer test in patients with coronary artery disease as well as ischemic heart disease in emergency medicine. Int J Cur Biomed Phar Res 2011; 1(2): 31-3.

13. Trukhacheva N.V. Mathematical statistics in biomedical research using Statistica. Moscow: GEOTARMedia; 2012. Russian (Трухачева Н.В. Математическая статистика в медико-биологических исследованиях с применением пакета Statistica. М.: ГЭОТАР- Медиа; 2012).

14. Bokarev I.N., Medvedev A.P. Laboratory Methods of blood clotting. Moscow: MOOSPITGIPS; 2012. Russian (Бокарев И.Н., Медведев А.П. Лабораторные методы исследования системы свертывания крови. Методические рекомендации. М.: МООСПИТГИПС; 2012).

15. Wu JF, Yang YH, Pang BS. Platelet factor 4 and β-thromboglobulin in blood plasma of patients with acute exacerbation of chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 2013;93(18):1378-82.

16. Lijun M, Ruixia Z, Zhentao S, et al. Blood Gas Analysis and Plasma D-dimer levels relationship in Chronic Obstructive Pulmonary Disease Patients. Life Sci J 2013;10(2):1668-70.

17. Yakusheva E.V., Polunina O.S., Voronina L.P., Prokof'eva T.V. Hemocoagulation shifts in chronic obstructive pulmonary disease. Uspekhi Sovremennogo Estestvoznaniya 2008; (5): 160.

18. Dart A, Sherrard B, Salem H. Protein S, von Willebrand factor, and euglobulin lysis time as markers of coronary heart disease. Ann Intern Med 1997; 126 (1): 89.

19. Rani MM, Nath KK, Mehrotra TN, Mishra SD. Fibrinolytic activity in coronary heart disease. J Postgrad Med 1981; 27:105.